Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market following launch. The report evaluates physicians’ current awareness and familiarity with Entyvio, its advantages and disadvantages compared with currently available therapies, the current and anticipated usage of the drug, as well as the manufacturer’s promotional activity.
Questions Answered in This Report:
- While there have been no reported cases of progressive multifocal leukoencephalopathy (PML) associated with Entyvio use to date, the mechanism of action has been a source of concern for specialists. Do there continue to be lingering concerns about the theoretical risk of PML?
- Entyvio represents a novel mechanism of action for the treatment of UC and CD. How have familiarity and satisfaction with Entyvio evolved since the drug was launched in UC and CD? What are the drug’s advantages and disadvantages in clinical practice according to gastroenterologists? How do these responses differ for Entyvio prescribers versus nonprescribers?
- There has historically been a high level of unmet need for more-efficacious therapies in the moderate to severe UC and CD markets. How is Entyvio addressing that need? Where are gastroenterologists placing Entyvio in their treatment algorithm for UC and CD, and for which patient types?
Markets covered: United States.
Primary research: 10 interviews with gastroenterologists, 73 surveyed gastroenterologists.